YU54301A - Konjugati gcsf - Google Patents

Konjugati gcsf

Info

Publication number
YU54301A
YU54301A YU54301A YUP54301A YU54301A YU 54301 A YU54301 A YU 54301A YU 54301 A YU54301 A YU 54301A YU P54301 A YUP54301 A YU P54301A YU 54301 A YU54301 A YU 54301A
Authority
YU
Yugoslavia
Prior art keywords
conjugates
gcsf conjugates
gcsf
conjugate
mixture
Prior art date
Application number
YU54301A
Other languages
English (en)
Inventor
Pascal Sebastian Bailon
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of YU54301A publication Critical patent/YU54301A/sh
Publication of RS50928B publication Critical patent/RS50928B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyethers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Opisani su fiziološki aktivni konjugati PEG-GCSF koji imaju formulu (I), kao i jedinjenja koja sadrže smešu svakog od konjugata u kojim m i n mogu biti različiti integrali za konjugate u jedinjenju.[Physiologically active PEG-GCSF conjugates having formula (I) are described, as well as compositions containing a mixture of each conjugate in which m and n can be different integers for the conjugates in the composition.
YUP-543/01A 1999-01-29 2000-01-19 Gcsf konjugati RS50928B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11791799P 1999-01-29 1999-01-29

Publications (2)

Publication Number Publication Date
YU54301A true YU54301A (sh) 2003-10-31
RS50928B RS50928B (sr) 2010-08-31

Family

ID=22375505

Country Status (26)

Country Link
US (4) US20030130193A1 (sh)
EP (1) EP1157037B1 (sh)
JP (1) JP2002540065A (sh)
KR (1) KR100689212B1 (sh)
CN (1) CN1376164A (sh)
AT (1) ATE246202T1 (sh)
AU (1) AU2618500A (sh)
BG (1) BG65213B1 (sh)
BR (1) BR0007781A (sh)
CA (1) CA2361766C (sh)
CZ (1) CZ300546B6 (sh)
DE (1) DE60004172T2 (sh)
DK (1) DK1157037T3 (sh)
EA (2) EA200400067A1 (sh)
ES (1) ES2204509T3 (sh)
HK (1) HK1049673A1 (sh)
HU (1) HU228488B1 (sh)
IL (1) IL144361A0 (sh)
MX (1) MXPA01007609A (sh)
NO (1) NO331787B1 (sh)
NZ (1) NZ513113A (sh)
PT (1) PT1157037E (sh)
RS (1) RS50928B (sh)
SK (1) SK286898B6 (sh)
WO (1) WO2000044785A1 (sh)
ZA (1) ZA200105932B (sh)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228488B1 (en) * 1999-01-29 2013-03-28 Amgen Inc Gcsf conjugates
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
JP5170931B2 (ja) 2000-10-16 2013-03-27 中外製薬株式会社 Ｐｅｇ修飾エリスロポエチン
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
CN102180944A (zh) * 2001-10-10 2011-09-14 诺和诺德公司 肽的重构和糖缀合
ZA200700168B (en) * 2001-10-10 2010-02-24 Novo Nordisk As Remodeling and glycoconjugation of peptides
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
AU2004236174B2 (en) 2001-10-10 2011-06-02 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
EA008505B1 (ru) * 2001-11-20 2007-06-29 Фармация Корпорейшн Конъюгаты химически модифицированного гормона роста человека
PL375265A1 (en) * 2002-07-24 2005-11-28 F.Hoffmann-La Roche Ag Polyalkylene glycol acid additives
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
WO2005018663A1 (en) * 2003-08-22 2005-03-03 The Council Of The Queensland Institute Of Medical Research G-csf derivative for inducing immunological tolerance
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
DK2586456T3 (en) 2004-10-29 2016-03-21 Ratiopharm Gmbh Conversion and glycopegylation of fibroblast growth factor (FGF)
EP1858543B1 (en) 2005-01-10 2013-11-27 BioGeneriX AG Glycopegylated granulocyte colony stimulating factor
US20060174362A1 (en) * 2005-02-01 2006-08-03 Origen Therapeutics, Inc. Long-term culture of avian primordial germ cells (PGCs)
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
CN101193658B (zh) 2005-06-01 2011-08-31 马克西根控股公司 聚乙二醇化g-csf多肽及其产生方法
AU2006259225B2 (en) 2005-06-16 2012-05-31 Nektar Therapeutics Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
WO2007019331A2 (en) * 2005-08-04 2007-02-15 Nektar Therapeutics Al, Corporation Conjugates of a g-csf moiety and a polymer
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
JP2007112924A (ja) * 2005-10-21 2007-05-10 National Institute For Materials Science 高分子架橋剤及びこの架橋剤を用いたリポソーム又は細胞の架橋体
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
CN101002943B (zh) * 2006-01-17 2012-02-01 中国科学院过程工程研究所 支链peg-gcsf和peg-gmcsf结合物及其制备方法
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
ITMI20061624A1 (it) 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
US20100316631A1 (en) * 2006-10-19 2010-12-16 The Uab Research Foundation Water Soluble Curcumin-Based Compounds
KR101079993B1 (ko) * 2006-11-17 2011-11-04 동아제약주식회사 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
JP2008125952A (ja) * 2006-11-24 2008-06-05 National Institute For Materials Science 複合架橋体
CN101245109B (zh) * 2007-02-12 2011-12-14 杭州九源基因工程有限公司 一种聚乙二醇单修饰的重组人粒细胞集落刺激因子突变体及其制备方法
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
ES2551123T3 (es) 2007-06-12 2015-11-16 Ratiopharm Gmbh Proceso mejorado para la producción de azúcares de nucleótido
CL2008002054A1 (es) 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
AR067537A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Purificacion de polipeptidos pegilados
CN101352573B (zh) * 2007-07-27 2011-02-09 杭州九源基因工程有限公司 聚乙二醇单修饰的重组人集落细胞刺激因子赖氨酸缺陷体
ES2523030T3 (es) 2008-02-18 2014-11-20 Jiangsu Hengrui Medicine Co., Ltd. Un conjugado del G-CSF modificado por un polímero hidrosoluble
MX2010009154A (es) 2008-02-27 2010-09-09 Novo Nordisk As Moleculas conjugadas del factor viii.
RU2409669C9 (ru) 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
EP2334699B1 (en) 2008-09-23 2013-09-11 F. Hoffmann-La Roche AG Purification of erythropoietin
BR112012019992A2 (pt) 2010-02-11 2020-08-18 F. Hoffmann-La Roche Ag. conjugados de igf-i poli (etileno glicol)
CA2808748C (en) 2010-09-14 2018-09-11 Roberto Falkenstein Method for purifying pegylated erythropoietin
US8889630B2 (en) 2011-12-23 2014-11-18 Carlos Lopez Method for hair regrowth using Granulocyte-Colony Stimulating Factor
PL3484911T3 (pl) 2016-07-15 2021-03-08 F. Hoffmann-La Roche Ag Sposób oczyszczania PEGylowanej erytropoetyny
CA3077215A1 (en) * 2017-10-11 2019-04-18 Elanco Us Inc. Porcine g-csf variants and their uses
EP3731873B1 (en) 2017-12-29 2022-01-26 F. Hoffmann-La Roche AG Process for providing pegylated protein composition
EP3731871B1 (en) 2017-12-29 2023-10-04 F. Hoffmann-La Roche AG Process for providing pegylated protein composition
EP3731872B1 (en) 2017-12-29 2021-11-24 F. Hoffmann-La Roche AG Process for providing pegylated protein composition
EP4267592A1 (en) * 2020-12-23 2023-11-01 Jazz Pharmaceuticals Ireland Ltd. Methods of purifying charge-shielded fusion proteins

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1609546A (en) * 1925-11-19 1926-12-07 Petroleum Rectifying Co Process of separating water from emulsions
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4514497B1 (en) * 1983-12-30 1998-02-24 Novagene Inc Modified live pseudorabies viruses
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
US5532341A (en) * 1985-03-28 1996-07-02 Sloan-Kettering Institute For Cancer Research Human pluripotent hematopoietic colony stimulating factor
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US5194592A (en) * 1986-12-23 1993-03-16 Kyowa Hakko Kogyo Co. Ltd. Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
ATE135370T1 (de) * 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3708151B2 (ja) * 1994-12-15 2005-10-19 協和醗酵工業株式会社 Ｐｅｇ化したヒト顆粒球コロニー刺激因子の定量法
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
KR0176625B1 (ko) * 1996-11-05 1999-04-01 삼성전자주식회사 적외선 물체검출장치
HU228488B1 (en) * 1999-01-29 2013-03-28 Amgen Inc Gcsf conjugates

Also Published As

Publication number Publication date
DE60004172T2 (de) 2004-04-22
CZ300546B6 (cs) 2009-06-10
WO2000044785A1 (en) 2000-08-03
NZ513113A (en) 2004-03-26
HK1049673A1 (zh) 2003-05-23
KR100689212B1 (ko) 2007-03-09
SK10352001A3 (sk) 2002-06-04
ES2204509T3 (es) 2004-05-01
ATE246202T1 (de) 2003-08-15
MXPA01007609A (es) 2003-06-24
EP1157037A1 (en) 2001-11-28
EA004685B1 (ru) 2004-06-24
HU228488B1 (en) 2013-03-28
AU2618500A (en) 2000-08-18
NO20013700L (no) 2001-09-25
HUP0203652A2 (hu) 2003-03-28
NO331787B1 (no) 2012-04-02
SK286898B6 (sk) 2009-07-06
RS50928B (sr) 2010-08-31
PL363117A1 (en) 2004-11-15
EP1157037B1 (en) 2003-07-30
CA2361766C (en) 2011-12-06
BG65213B1 (bg) 2007-07-31
HUP0203652A3 (en) 2005-01-28
EA200100838A1 (ru) 2002-04-25
BG105851A (en) 2002-06-28
DE60004172D1 (de) 2003-09-04
US20050196378A1 (en) 2005-09-08
JP2002540065A (ja) 2002-11-26
CA2361766A1 (en) 2000-08-03
US20070219356A1 (en) 2007-09-20
IL144361A0 (en) 2002-05-23
CZ20012654A3 (cs) 2002-05-15
US20080287659A1 (en) 2008-11-20
ZA200105932B (en) 2002-10-18
DK1157037T3 (da) 2003-11-24
CN1376164A (zh) 2002-10-23
NO20013700D0 (no) 2001-07-27
KR20020007296A (ko) 2002-01-26
EA200400067A1 (ru) 2004-04-29
PT1157037E (pt) 2003-12-31
US20030130193A1 (en) 2003-07-10
BR0007781A (pt) 2002-02-05

Similar Documents

Publication Publication Date Title
MXPA01007609A (es) Gcsf conjugados.
EP1100522A4 (en) ADMINISTRATION OF ACTIVE SUBSTANCES BY PULMONARY TRACT
HK1048990A1 (en) Novel compounds.
IL150986A0 (en) 1,2,3,4,- tetrahydroisoquinoline derivatives
DE69835201D1 (en) Neoglycoproteine
AU3435497A (en) Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies
HRP20031003A2 (en) 4'-substituted nukleosides
BG105564A (en) Galantamine-containing composition with controlled release
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
IL140437A0 (en) Pharmaceutical compositions comprising 2-quinolines
CA2335551A1 (en) Thyroid hormone analogues and methods for their preparation
IL150061A0 (en) Purine derivatives
GEP20063972B (en) Streptogramin derivatives, preparation and compositions containing them
EP1379508A4 (en) N- (ARYL) -2-ARYLETHESULFONAMIDES AND THEIR THERAPEUTIC APPLICATIONS
YU59400A (sh) Azabiciklični ligandi 5ht1 receptora
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
ATE268175T1 (de) Decursin-enthaltende pharmazeutische zusammensetzungen
ZA991546B (en) Streptogramin derivatives, their preparation and compositions containing them.
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
ES2159260A1 (es) Nueva composicion de metanosulfonato de paroxetina
YU72802A (sh) Farmaceutske smeše koje sadrže oligosaharide, novi oligosaharidi i njihovo dobijanje
MXPA03010259A (es) Nuevos derivados de 5-tio-ss-d-xilopiranosida, procedimiento de preparacion, composiciones farmaceuticas que los contienen y el uso terapeutico de los mismos.
YU5302A (sh) Derivati streptogramina, njihovo dobivanje i smeše koje ih sadrže
YU23498A (sh) Herbicidni 3,5-difluoropiridini